Neurvati Neurosciences, a US-based clinical-stage biotechnology company, announced on Monday that it has named Dr Deborah Dunsire as a new member and the new chair of the company's board of directors.

Dr Dunsire has worked as CEO of H Lundbeck A/S, president, CEO and a director of XTuit Pharmaceuticals, Inc, and president, CEO and a director of FORUM Pharmaceuticals. She has served at Takeda Pharmaceutical Company as a corporate officer and director and as president, CEO and a director of Millennium Pharmaceuticals, Inc. She has served in various roles of increasing responsibility at Novartis Pharma AG. Presently, Dr Dunsire serves as a director of Syros Pharmaceuticals and Ultragenyx.

Bruce Leuchter, M.D., Neurvati president and chief executive officer, said, 'We are very excited to welcome Dr Dunsire to the Neurvati board of directors. She is a renowned industry veteran with a proven track record of success in leading the development and management of neuroscience companies, most recently as CEO of H. Lundbeck A/S where she led the company through a period of significant growth. As we plan for several important milestones in both our clinical development programs and our business strategy, her insights and global reach within the neuroscience community will play a central role in helping us continue our progress and achieve new levels of momentum. We very much look forward to working with her.'